Lactobacillus rhamnosus Granules Dose-Dependently Balance Intestinal Microbiome Disorders and Ameliorate Chronic Alcohol-Induced Liver Injury

J Med Food. 2020 Feb;23(2):114-124. doi: 10.1089/jmf.2018.4357. Epub 2019 Nov 20.

Abstract

As the functions of Lactobacilli become better understood, there are increasing numbers of applications for Lactobacillus products. Previously, we have demonstrated that Lactobacillus rhamnosus GG (LGG) can prevent alcoholic liver injury. LGG granules were produced by fluid bed granulation with a media composed of starch, skimmed milk powder, whey powder, microcrystalline cellulose and maltose, and LGG fermented liquid that comprised 30-50% of the total weight. We found LGG granules dose-dependently protected against chronic alcoholic liver disease. When alcohol was consumed for 8 weeks with LGG treatment during the last 2 weeks, we demonstrated that the dose dependence of LGG granules can improve alcohol-induced liver injury through decreasing the levels of lipopolysaccharide and tumor necrosis factor-α in serum and prevent liver steatosis by suppressing triglyceride, free fatty acid, and malondialdehyde production in liver. Alcohol feeding caused a decline in the number of both Lactobacillus and Bifidobacterium, with a proportional increase in the number of Clostridium perfringens in ileum, and expansion of the Gram-negative bacteria Proteobacteria, Campylobacterales, and Helicobacter in cecum. However, LGG granule treatment restored the content of these microorganisms. In conclusion, LGG granule supplementation can improve the intestinal microbiota, reduce the number of gram-negative bacteria, and ameliorate alcoholic liver injury.

Keywords: Lactobacillus rhamnosus GG granules; alcohol; intestinal flora; liver injury.

MeSH terms

  • Alanine Transaminase / blood
  • Animals
  • Aspartate Aminotransferases / blood
  • Bifidobacterium / growth & development
  • Campylobacterales / growth & development
  • Chemical and Drug Induced Liver Injury, Chronic / microbiology*
  • Chemical and Drug Induced Liver Injury, Chronic / therapy*
  • Clostridium perfringens / growth & development
  • Gastrointestinal Microbiome / genetics
  • Gastrointestinal Microbiome / physiology*
  • Helicobacter / growth & development
  • Ileum / microbiology
  • Intestines / microbiology*
  • Lacticaseibacillus rhamnosus / physiology*
  • Lactobacillus / growth & development
  • Male
  • Malondialdehyde / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Probiotics / therapeutic use*
  • Proteobacteria / growth & development
  • RNA, Ribosomal, 16S / genetics
  • RNA, Ribosomal, 16S / isolation & purification
  • Triglycerides / blood
  • Tumor Necrosis Factor-alpha / blood

Substances

  • RNA, Ribosomal, 16S
  • Triglycerides
  • Tumor Necrosis Factor-alpha
  • Malondialdehyde
  • Aspartate Aminotransferases
  • Alanine Transaminase